Breij, Esther C. W.

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 521

Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors

Boshuizen, J., Koopman, L. A., Krijgsman, O., Shahrabi, A., van den Heuvel, E. G., Ligtenberg, M. A., Vredevoogd, D. W., Kemper, K., Kuilman, T., Song, J.-Y., et al. (2018) · Nature Medicine

Melanoma and MAPK PathwaysCancer Immunotherapy and Biomarkers

Cited by 229

An Antibody–Drug Conjugate That Targets Tissue Factor Exhibits Potent Therapeutic Activity against a Broad Range of Solid Tumors

Breij, E. C. W., de Goeij, B. E. C. G., Verploegen, S., Schuurhuis, D. H., Amirkhosravi, A., Francis, J., Miller, V. B., Houtkamp, M., Bleeker, W. K., Satijn, D., et al. (2014) · Cancer Research

Monoclonal and Polyclonal Antibodies ResearchToxin Mechanisms and Immunotoxins

Cited by 227

The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions

Brink, B. P., Veerhuis, R., Breij, E. C. W., van der Valk, P., Dijkstra, C. D., & Bö, L. (2005) · Journal of Neuropathology & Experimental Neurology

Multiple Sclerosis Research StudiesComplement system in diseases

Cited by 191

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

Engelberts, P. J., Hiemstra, I. H., de Jong, B., Schuurhuis, D. H., Meesters, J., Beltran Hernandez, I., Oostindie, S. C., Neijssen, J., van den Brink, E. N., Horbach, G. J., et al. (2020) · EBioMedicine

Monoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and Treatment

Cited by 172

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

van der Horst, H. J., de Jonge, A. V., Hiemstra, I. H., Gelderloos, A. T., Berry, D. R. A. I., Hijmering, N. J., van Essen, H. F., de Jong, D., Chamuleau, M. E. D., Zweegman, S., et al. (2021) · Blood Cancer Journal

Lymphoma Diagnosis and TreatmentCAR-T cell therapy research

Cited by 86

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting

Mhibik, M., Gaglione, E. M., Eik, D., Herrick, J., Le, J., Ahn, I. E., Chiu, C., Wielgos-Bonvallet, M., Hiemstra, I. H., Breij, E. C. W., et al. (2023) · Blood Advances

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 43